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Abstract
Background: Lysophosphatidic acid (LPA) governs a number of physiologic and pathophysiological processes. Malignant
ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the
initiation and progression of ovarian cancer. However, there is an absence of systematic data critically analyzing the
transcriptional changes induced by LPA in ovarian cancer.
Methodology and Principal Findings: In this study, gene expression profiling was used to examine LPA-mediated
transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in
the tumor microenvironment. The resultant transcriptional profile comprised a 39-gene signature that closely correlated to
serous epithelial ovarian carcinoma. Hierarchical clustering of ovarian cancer patient specimens demonstrated that the
signature is associated with worsened prognosis. Patients with LPA-signature-positive ovarian tumors have reduced
disease-specific and progression-free survival times. They have a higher frequency of stage IIIc serous carcinoma and a
greater proportion is deceased. Among the 39-gene signature, a group of seven genes associated with cell adhesion
recapitulated the results. Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only
independent biomarker of serous epithelial ovarian carcinoma. Knockdown of claudin-1 expression in ovarian cancer cells
reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
Conclusions: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor
progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated
expression signature in ovarian cancer that predicts a worse prognosis.
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Introduction
The relationship between lysophosphatidic acid (LPA) and the
tumor microenvironment remains poorly understood. Although
LPA is secreted by ovarian cancer cells [1], found at elevated
concentrations in ascites fluid [2–5], and LPA receptors are
aberrantly expressed in ovarian cancer [6,7] it is not known
whether LPA in the tumor microenvironment activates transcrip-
tional events contributing to the etiology and/or progression of the
ovarian cancers. The hypothesis that ascites-borne LPA functions
in a pathophysiological context is based on several observations.
First, exogenous LPA causes cell proliferation, survival, invasion,
migration and production of angiogenic factors likely to contribute
to tumorigenesis [8]. Second, LPA receptor expression is altered in
ovarian carcinomas [7,9]. Third, gene expression of LPPs, the
naturally occurring enzymes that hydrolyze LPA, is decreased in a
significant fraction of ovarian carcinomas [9]. Fourth, enforced
expression of LPPs reduces ovarian cancer cell tumorigenesis [10].
Fifth, inhibitors of autotaxin (ATX), the enzyme that generates
LPA, reduce both invasion and metastasis in vivo [11].
It is important to determine whether there is a relationship
between LPA and patient outcomes since epithelial ovarian cancer
(EOC) is the fifth leading cause of cancer mortality for women in
the U.S. [12]. Serous epithelial carcinoma accounts for about 70%
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poor survival [13]. Serous tumor cells most closely resemble
epithelial cells from the fallopian tubes and at least half of all
serous tumors are invasive (malignant) with another fraction
borderline (low malignant potential) or benign [14]. Peritoneal
spread is a primary factor causing ovarian cancer related
morbidity and mortality. Since ovarian cancer develops within
the peritoneal cavity, its location facilitates a unique version of
metastasis as cells shed from the primary ovarian tumor are
passively transported through fluid to surrounding tissues, unlike
most metastatic tumors [15]. This passive mechanism bypasses
many challenging processes facing metastatic tumor cells: intrava-
sion, extravasion, degradation and adhesion.
The latter function, cell adhesion, is critical because strong
adhesive anchoring to the extracellular matrix is one of two
required signals needed for normal cells to thrive, the other is
adequate levels of growth factors [16]. The mitogenic growth
factor, LPA, indeed enhances cell growth, viability and prolifer-
ation of adherent cells [17]. Furthermore, under stress conditions
associated with low fibronectin, Chinese hamster ovary cells
stimulated with LPA demonstrated significantly enhanced viability
and dramatically reduced apoptosis [18]. This data suggests that
LPA may have an additional role to enhance cell adhesion
contacts with the extracellular matrix under the stress conditions
associated with tumor development and spread.
Normal ovarian surface epithelium rarely expresses the
epithelial adhesion molecule E-cadherin, yet increased E-cadherin
expression is found in metaplastic ovarian surface epithelium and
primary epithelial ovarian carcinomas, suggesting cell adhesion
molecules are involved in ovarian neoplastic progression [19].
Cultured ovarian surface epithelial cells frequently resemble
fibroblasts, lack cytokeratins and reflect a mesenchymal phenotype
conversion. Restored expression of the adhesion molecule E-
cadherin reinstates epithelial properties to the cultured cells,
marked by tight junctions; [19]. Other adhesive molecules may
play a role in the polarity of ovarian epithelial cells , such as
claudins, a 24-member family of 20–26 kDa proteins that localize
to tight junctions in order to maintain cell-cell adhesion and inhibit
any unregulated flow of solutes into tissues.
We sought to better understand how LPA in the microenvi-
ronment impacts molecular ovarian cancer progression by
examining gene expression changes induced by LPA in ovarian
cancer cell lines. Herein we establish a transcriptional profile of 39
LPA-induced genes in OVCAR-3 ascites-derived cells. Applying
the available genes from the transcriptional signature to ovarian
cancer patient specimens taken during the debulking surgical
procedure demonstrated an ability of the signature to predict
patient prognosis. This transcriptional profiling uncovered an
LPA-mediated increase in claudin-1 (CLDN1), an adhesion
molecule that is inherently associated with tight junctions, cell
adhesion and epithelial cell morphology. The transcriptional
increase observed in CLDN1 correlated with serous ovarian cancer
after analysis with ovarian cancer patient profiles, suggesting that
LPA may play a molecular role in plasticity of the histology of
ovarian cancer. The present study addresses the prognostic value
of LPA profiling, provides insight into LPA signaling in the tumor
microenvironment and suggests specific LPA-induced genes that
may contribute to ovarian cancer progression.
Methods
Reagents and materials
LPA (18:1, 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) was pur-
chased from Avanti Polar Lipids Inc (Alabaster, AL). OVCAR-3
ovarian epithelial adenocarcinoma and SKOV-3 ovarian serous
adenocarcinoma cells were acquired from ATCC (Manassas, VA)
and maintained in RPMI (CCSG Media Preparation Facility, The
University of Texas M. D. Anderson Cancer Center, Houston, TX)
supplemented with 10% FBS (Sigma, St Louis, MO). HT-29
human colon cancer cells were maintained in DMEM (CCSG
Media Preparation Facility) supplemented with 10% FBS (Sigma).
The claudin-1 antibody waspurchasedfrom Zymed (San Francisco,
CA) and the GAPDH antibody was purchased from Applied
Biosciences/Ambion (Austin, TX).
LPA-induced gene expression
OVCAR-3 cells were serum-starved prior to stimulation with
20 mM 18:1 LPA, 20 nM EGF or 2 mM TGFb for 24 h to mimic
long-term LPA influence in the ovarian tumor microenvironment.
Pathological LPA concentrations range from 1 to 80 mM and LPA
is rapidly degraded in vitro justifying the use of 20 mM LPA in the
cultures. RNA was extracted using a Qiagen kit (Qiagen, Valencia,
CA) and TRIzol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Gene expression microarray profiling
was performed using triplicate sample on Affymetrix GeneChip
U133A GeneChips on an HTA system at the Life Sciences
Division of the Ernest Orlando Lawrence Berkeley National
Laboratory (Berkeley, CA). Data was uploaded to the GeneTraffic
Bioinformatics server with GeneTraffic microarray database and
analysis software (Stratagene/Agilent Technologies, La Jolla, CA)
for raw image analysis, filtering and processing.
Data analysis for transcriptional signatures
Linear scale data from the GeneTraffic algorithm was
transformed to log2. Significance Analysis of Microarrays (SAM)
[20 R., and Chu, G. 2001], implemented as the R package samr
(version 1.20) (http://www-stat.stanford.edu/,tibs/SAM/Rdist/
index.html), was used for statistical analysis. The mean expression
levels between the LPA-treated and the control groups for
significant changes had parameters set such that resp.type=‘Two
class unpaired’, nperm=100, testStatistic=‘standard’, and delta=0.5.
The final cutoff q-value [21] was 5%. This resulted in 45 up-
regulated transcripts, with repeats, giving 39 uniquely-expressed
transcripts. Among these genes, 90% had a fold change $1.4.
Categorization of the LPA signature
Gene lists generated from microarray analysis were probed for
biological themes using Expression Analysis Systematic Explorer
(EASE) analysis tool [22]. This application converts gene lists into
biologically relevant categories to aid the interpretation of
microarray data. List results were converted into pie graphs using
Microsoft Excel to aid visual interpretation.
Cluster analyses
Hierarchical clustering analyses used Cluster developed by the
Eisen lab [23]. Genes were median centered prior to clustering.
Cluster processed the data by selecting both genes and arrays and
creating average linkage. The display of hierarchical clustering
graphs utilized TreeView [23]. For hierarchical clusters, publicly-
available ovarian cancer gene expression datasets (GSE6822 [24],
GSE6008 [25], GSE10971 and GSE12418 [26]) were downloaded
from the NCBI Entrez GEO website (http://www.ncbi.nlm.nih.
gov/sites/entrez?db=gds).
Real-time quantitative PCR
Transcripts in the 39-gene expression profile not previously
implicated in LPA signaling were verified with real-time QPCR.
LPA Gene Expression Profile
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Aldrich, St. Louis, MO). Using 300 ng of mRNA as a template, a
reverse transcription reaction was performed using Superscript III
kit (Invitrogen, Carlsbad, CA) to generate cDNA following the
manufacturer’s protocol. Quantitative PCR was performed using
SYBR Green PCR Master kit (Applied BioSystems, Foster City,
CA). Reactions were normalized using the housekeeping gene, b2-
microglobulin, and calculations were performed according to
previous methods [27]. Primers used were based on algorithm-
generated sequences from Primer Bank (http://pga.mgh.harvard.
edu/primerbank/) [28]. The results presented used: ATF3 (59-
TCTGCGCTGGAATCAGTCAC-39 and 59-GTGGGCCGAT-
GAAGGTTGA-39); CLDN1 (59-GCGCGATATTTCTTCTTG-
CAGG-39 and 59-TTCGTACCTGGCATTGACTGG-39); ETV5
(59-GCTGTCGTCTTGTAGCCATGA-39 and 59-GGGATTCT-
GATGGGTGGGT-39); EPAS1 (59-CGGAGGTGTTCTATGA-
GCTGG-39 and 59-GCTTGTGTGTTCGCAGGAAG-39);
LDLR (59-TCTGTCTCGAGGGGTAGCTG-39 and 59-CAAT-
GTCTCACCAAGCTCTG-39); b2-microglobulin (59-GTGG-
CCTTAGCTGTGCTCG-39 and 59-ACCTGAATGCTGGATA-
GCCTC-39); MUC1 (59-AAGCAGCCTCTCGATATAACCT-39
and 59-GGTACTCGCTCATAGGATGGT-39); and SKIL (59-
AATCAATCCAAGACAGATGCACC-39 and 59-AGTTTACC-
ACTACTGTGAGCCTT-39).
Claudin-1 fluorescent visualization
Fluorescence imaging was done as previously described [17]. In
order to asses the localization of claudin-1 after LPA addition,
quiescent HT-29 and OVCAR-3 cells were stimulated with LPA
(10 mM) for the times indicated and visualized using anti-claudin1
primary antibody (1:200; Zymed) followed by Oregon Green-
conjugated goat anti-mouse immunoglobulin G (1:500; Invitro-
gen/Molecular Probes) secondary antibody.
Boyden chamber migration assay
SKOV-3 cells (2610
5) were transfected with reagent only, no
siRNA (Mock), RISC-free control siRNA or claudin-1 siRNA.
Forty-eight hours later, cells were seeded into the upper wells of a
membrane Boyden chamber and migration assay done as
described [17]. Results were repeated and confirmed by crystal
violet extraction using 10% acetic acid and measuring the OD at
590 nm.
Two-dimensional cell motility
SKOV-3 cells transfected with siRNA were grown to conflu-
ence. Two-dimensional cell motility assay was done as previously
described [17]. Cells between monolayers were counted and data
is averaged over all experiments. Displayed photomicrograph
images (46) are representative of repeated experiments.
Western blot assessment of siRNA transfection
Protein from SKOV-3 cells transfected with siRNA was
harvested and processed for Western blotting as previously
described [17]. Immunoblots were probed with claudin-1 (Zymed)
and GAPDH (Applied Biosciences/Ambion) antibodies and
visualized with chemiluminescence. Band intensities were normal-
ized to Mock control and represent the ratio of peak values.
Cell proliferation and viability
SKOV-3 cells transfected with siRNA using in motility studies
were examined for viability by detaching cells from 12-well dishes
and plating 5, 10 or 15, 20610
4 cells in 96-well plates in
quadruplicates. Cells were grown for 24 h in 1% medium before
adding CellTiter
TM Blue reagent (Promega, Madison, WI) to wells
to measure viability as previously described [17].
Cell adhesion
OVCAR-3 cells were transfected with siRNA for 48 h prior to
examination for cell adhesion. Cells were seeded at 5610
4 cells in
96-well plates in quadruplicates for 2 h before multiple washings
with PBS. Calcein-AM solution was then added to each well of the
96-well plate and fluorescence was measured.
Patient outcome, sensitivity, and specificity analyses
Patient data for disease-specific (DSS) and progression-free
survival (PFS) were obtained from clinical reports. For this study,
ovarian cancer specimens (N=79) were obtained at the debulking
surgical procedure from patients treated at the Department of
Gynecological Oncology at The Norwegian Radium Hospital
(NRH) during the period May 1992 to February 2003. Tumor
tissues were obtained at primary surgery and were snap frozen in
liquid nitrogen. Expression arrays were run on all tumor
specimens (N=79) and clinical data were available for 79 tumors.
The median age of the patients at diagnosis was 60 years (range,
38–81). The stage distribution of these ovarian cancers at diagnosis
was as follows: stage IIB (1), stage IIC (6), stage IIIB (1), stage IIIC
(54) and stage IV (17). The majority of ovarian cancers were of
high grade (grade 1 (5), grade 2 (18), grade 3 (56)) and serous in
histology (serous (65), endometrioid (4), mucinous (3), undifferen-
tiated (2), mixed (1), clear cell (1), unclassified (3)). Fifty-seven
patients developed progressive disease at a median of 15 months
(range, 3–126). In those patients without disease progression,
follow-up ranged from 77–128 months. Progression-free survival
(PFS) was measured from the date of surgery to the date of ovarian
cancer progression. Disease-specific survival was measured from
the date of surgery to the date of death from ovarian cancer.
Sensitivity and specificity
The data were plotted in a Kaplan-Meier survival curve format
using GraphPad Prism software, which automatically generates p
values for the survival curve (GraphPad Software, Inc., San Diego,
CA). To ascertain data quality, we employed two supervised
classification analyses: linear discrimination analysis (LDA) and K-
nearest neighbor classification (KNN). Four of the 60 patients that
had reported PFS time had more than 10 missing values, and they
were excluded before imputing missing data according to the
following protocols: http://www-stat.stanford.edu/hastie/Papers/
missing.pdf [29]. Using the statistical parameters, with leave-one-
out cross-validation, we achieved high sensitivity (0.88 and 0.94 for
LDA and KNN, respectively) and low specificity (0 and 0.25 for
LDA and KNN, respectively) for predicting relapse. We also took
the 52 patients that have long (.6 mo.) and short (,=6 mo.)
relapse time for the same kinds of supervised classification. Using
the same methods, we obtained very low sensitivity (0.29 and 0 for
LDA and KNN respectively) and high specificity (0.84 and 0.91
for LDA and KNN, respectively) for predicting short relapse. The
overall error rates for LDA and KNN are 0.17 and 0.1, resp., for
the first analysis and 0.23 and 0.21, respectively, for the second
analysis.
Statistical analysis
Experimental data was analyzed for statistical differences using
an analysis of variance (ANOVA) followed by Bonferroni’s
Multiple Comparison test or Tukey’s test between groups or
student’s t-test for comparison when the two compared categories
have variances assumed equal. Tests applied where indicated and
LPA Gene Expression Profile
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*p,0.05 **p,0.01 and ***p,0.001 indicate the levels of
significance.
Results
The 39-gene, LPA-mediated transcriptional signature
encompasses carcinogenesis-related transcripts
In order to define a molecular signature regulated by LPA
reflective of the ovarian tumor microenvironment, we employed
microarray expression profiling using ascites-derived OVCAR-3
ovarian adenocarcinoma cells. Our intention was to uncover LPA-
induced transcriptional changes that result from long-term
autocrine and paracrine LPA signaling in the tumor microenvi-
ronment. For this purpose we stimulated OVCAR-3 cells in
culture with LPA (20 mM) for 24 h to mimic chronic exposure. We
analyzed the microarray results using the statistical analysis of
microarray (SAM) program, which yielded 45 positive hits. The
results included several transcript repeats, totaling 39 different
genes altogether to comprise a ‘‘39-gene’’ signature (Table 1). LPA
has been demonstrated to regulate six of these genes, including
CXCL1 [30], CYR61 [31], EGR1 [32], IL-8 [33], FN1 [34] and
PLAU [35], while the remainder were known genes that had
unknown associations with LPA. FN1, MUC1, SCD and THBS1,
appear more than once providing a level of signature validation.
To determine the data quality, we created pairwise scatter plots
and cross-compared the triplicate microarray data using control
(Figure S1A), LPA treated (Figure S1B) and EGF treated (Figure
S1C) samples. The scatter plots demonstrate a high degree of
reproducibility with microarray replicates, falling close to a 45u
reference line. The statistical corroboration enhances the likeli-
hood that transcripts, which have no known connection to LPA
are legitimate targets.
For further verification, we performed a time course followed
with quantitative RT-PCR on the majority of transcripts with
unknown associations to LPA, excluding CXCL1, CYR61, EGR1,
IL-8, FN1 and PLAU. Thus, we analyzed 88% (N=29) in
OVCAR-3 and 91% in SKOV-3 (N=30). SKOV-3 cells were
selected to determine the generalizability of the results obtained
with OVCAR-3 cells. The data shown confirms LPA-mediated
modulation of expression among the transcription factors, ATF3,
EPAS1, ETV5 and SKIL (transcriptional co-repressor), appearing
in the gene expression microarray data (Figure S1D). During this
verification process of the 39-gene signature, we uncovered two
genes, LOX and TNFAIP3, increased in the microarray results but
decreased in quantitative RT-PCR (asterix in Table 1 and data
not shown). The reason for the differential response in the two
assays remains unknown.
Using EASE, we classified the 39 genes comprising the LPA
signature into two groups: cellular localization and molecular
function. The principal location of one third of 39 genes was the
plasma membrane, (Figure S1E). The next most common location
was the cytoplasm (26%). Interestingly, over half of the genes in
the signature produce secreted proteins (20%) or proteins that are
found in regions of the cell that would allow extracellular signaling,
like the extracellular matrix (12%) and plasma membrane (30%).
When we examined the molecular function of the 39-gene LPA
signature, cell-cell communication was the leading represented
category (21%) followed by signal transduction (14%) (Figure S1F).
A wide variety of molecular functions were also included such as
cell growth (13%), adhesion (13%), proliferation (11%), general
cell metabolism (9%), lipid metabolism (7%) and products
associated with the regulation of either survival or apoptosis (5%).
The 39-gene, LPA-mediated signature correlates with
serous carcinoma and worse prognosis in ovarian cancer
patients
Hierarchical clustering using the 39-gene signature and an
ovarian cancer training dataset from M.D. Anderson Cancer
Center with control/non-malignant and serous EOC revealed a
highly similar pattern among patient specimens (data not shown).
The training data suggested LPA influences the development of
serous EOC and/or the 39-gene signature characterizes serous
EOC. To test these hypotheses, we analyzed additional datasets
including a test dataset (GSE6008; N=103) [24] containing
normal ovary specimens and ovarian tumors from endometrioid,
mucinous, serous and clear cell types.
Hierarchical clustering analysis of GSE6008 demonstrated that
the most positive cluster for the 39-gene signature contained only
serous specimens (N=19, 100%) (Figure 1, far right cluster).
Within the overall hierarchical clustering results, the gene
expression dataset was divided into two major groups (N=55
and 44) with normal ovary (N=4) in the middle, separating the
two. The group on the right (N=55) that contained the highly
positive LPA-signature cluster and additional clusters varying in
LPA-signature-likeness, consisted primarily of serous (N=29,
71%, P,0.001) or endometrioid (N=23, 62%, P=0.016) tumors.
The group on the left (separated by normal samples) exhibited
expression patterns which deviate from the LPA-signature and
consisted of clear cell (100%, P=0.002), mucinous (77%,
P=0.018), endometrioid (38%, P=0.016) and a portion of serous
(29%, P,0.001) tumors. It is important to note that the majority
of the serous tumors on the left side show a distinct expression
pattern that deviates from clear cell and mucinous tumors that are
negative for the LPA-signature.
To further verify that 39-gene signature characterizes serous
EOC, we examined additional ovarian datasets. The dataset
GSE6822 (N=74) [25] contains a majority of serous specimens
(N=46, 62%) and includes benign, borderline and invasive
tumors. It is extremely difficult to acquire reliable, high-quality
ovarian cancer datasets that include patient outcomes, as few are
publicly available. Thus, the dataset we acquired has some
incomplete data (gray shaded areas) and missing genes but we
nonetheless used it for analysis knowing this limitation. Hierar-
chical clustering separated a group (N=19) that was strongly
positive for the LPA-signature (Figure S2A, far right cluster). The
majority of tumors within this cluster are invasive serous tumors
(63%) with a greater proportion of invasive tumors (90%) than
other clusters (78%). Among the other clusters, which do not
represent a likeness to the LPA-signature, the invasive serous is
underrepresented (36% of the remaining tumors), whereas benign
serous (83%) and borderline serous (88%) tumors are highly
represented. In addition, these other clusters comprise a variety of
ovarian tumor types such as clear cell (15%), endometrioid (13%),
undetermined origin (11%), mixed (2%) and mucinous (2%), while
the LPA-signature is strongly dominated by serous tumors (74%)
and has no endometrioid, mucinous or tumors of undetermined
origin. Over half of all serous tumor cells are invasive (malignant)
and the remaining are borderline (low malignant potential) or
benign [14].
Another dataset GSE10971 (N=37) contains samples from
non-malignant fallopian tube epithelium and high-grade serous
carcinoma. Hierarchical clustering divided the samples into two
groups (data not shown). Among the LPA-positive cluster, all
samples were high-grade serous (N=12, 100%) and among the
dissimilar cluster, nearly all samples were non-malignant (N= 24,
96%) (Figure S2B). Only one sample from the latter group was
high-grade serous (N=1, 4%). In summary, the data from our
LPA Gene Expression Profile
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signature in OVCAR-3.
Probe ID Symbol Description Fold change q-value (%)
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3B
1.8724 2.377
202672_s_at ATF3 activating transcription factor 3 2.3955 0
218182_s_at CLDN1 claudin 1 1.7531 4.5221
204470_at CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha)
1.7242 4.5221
210764_s_at CYR61 cysteine-rich, angiogenic inducer, 61 1.722 2.377
204135_at DOC1 downregulated in ovarian cancer 1 2.2444 0
203498_at DSCR1L1 down syndrome critical region gene 1-like 1 1.9364 0
201694_s_at EGR1 early growth response 1 1.446 0
201313_at ENO2 enolase 2 (gamma, neuronal) 1.5517 0
200878_at EPAS1 endothelial PAS domain protein 1 1.3329 4.5221
203349_s_at ETV5 ets variant gene 5 (ets-related molecule) 1.3894 4.5221
205014_at FGFBP1 fibroblast growth factor binding protein 1 2.5373 0
211719_x_at FN1 fibronectin 1 2.3993 2.377
212464_s_at FN1 fibronectin 1 2.2809 2.377
216442_x_at FN1 fibronectin 1 2.2851 2.377
201631_s_at IER3 immediate early response 3 1.857 0
202421_at IGSF3 immunoglobulin superfamily, member 3 1.2985 4.5221
202859_x_at IL8 interleukin 8 3.9342 0
218963_s_at KRT23 keratin 23 (histone deacetylase inducible) 1.9927 0
202068_s_at LDLR low density lipoprotein receptor (familial
hypercholesterolemia)
1.5159 0
220158_at LGALS14 lectin, galactoside-binding, soluble, 14 1.6646 0
215446_s_at * LOX lysyl oxidase 1.4016 2.377
212233_at MAP1B microtubule-associated protein 1B 1.9061 0
207847_s_at MUC1 mucin 1, transmembrane 1.7853 0
211695_x_at MUC1 mucin 1, transmembrane 2.0686 4.5221
211017_s_at NF2 neurofibromin 2 (bilateral acoustic neuroma) 1.4298 0
219369_s_at OTUB2 OUT domain, ubiquitin aldehyde binding 2 1.511 4.5221
211668_s_at PLAU plasminogen activator, urokinase 1.8944 2.377
204286_s_at PMAIP1 phorbol-12-myristate-13-acetate-inducible protein 1 1.4263 0
210138_at RGS20 regulator of G-protein signaling 20 1.5114 2.377
200831_s_at SCD stearoyl-CoA desaturase (delta-9-desaturase) 1.4012 0
200832_s_at SCD stearoyl-CoA desaturase (delta-9-desaturase) 1.375 2.377
206884_s_at SCEL sciellin 1.823 0
33323_r_at SFN stratifin 1.8976 2.377
206675_s_at SKIL SKI-like 1.3488 2.377
202856_s_at SLC16A3 solute carrier family 16 (monocarboxylic acid transporter)
member 3
1.6286 2.377
201195_s_at SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+
system) member 5
1.6561 0
201109_s_at THBS1 thrombospondin 1 1.9995 0
201110_s_at THBS1 thrombospondin 1 2.085 0
219058_x_at TINAGL1 tubulointerstitial nephritis antigen-like 1 1.4088 2.377
217875_s_at TMEPAI transmembrane, prostate androgen induced RNA 1.9765 0
201645_at TNC tenascin C (hexabrachion) 1.5708 0
202643_s_at * TNFAIP3 tumor necrosis factor, alpha-induced protein 3 1.8922 0
202644_s_at * TNFAIP3 tumor necrosis factor, alpha-induced protein 3 1.6207 0
212242_at TUBA1 tubulin, alpha 1 (testis specific) 1.9468 0
*Denotes decrease in transcript analyzed during verification using real-time QPCR.
doi:10.1371/journal.pone.0005583.t001
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GSE10971 and GSE6008 datasets suggests that the LPA-signature
characterizes serous EOC.
Since evidence suggests the 39-gene signature characterizes
serous EOC from ovarian datasets (Figure 1, Figure S2A and S2B,
and data not shown), we questioned whether it also classified
prognosis in ovarian cancers. For this analysis, we acquired two
ovarian cancer datasets containing patient outcomes. The first
dataset (GSE12418; N=54) [26] was used to examined the
predictive value of the 39-gene signature and it contains serous
samples from different stages. Hierarchical clustering separated the
specimens into two groups (Figure 2A) based largely upon drivers
THBS1, EGR1, EPAS1, CYR61, FN1 and PLAU. The LPA-
signature-positive cluster (N=24) contained a greater portion of
samples from stage IIIc patients (N=20, 83%, P=0.01) than the
dissimilar cluster that was evenly split among stage IIIa, IIIb and
IIIc (Figure 2B). Although not statistically significant, samples in
the LPA-positive cluster also contained more deceased patients
(N=18; 67%) than the dissimilar cluster (N=16, 53%) (Figure 2C).
The second ovarian cancer dataset containing patient outcomes
that we used for the prognosis analysis is a large EOC dataset
(N=79, see METHODS for more details) of specimens acquired
from patients treated at the Norwegian Radium Hospital. Briefly,
the ovarian cancer specimens were obtained at the debulking
surgical procedure from primary tumors. Hierarchical clustering
separated the patients into three groups (Figure 2D) based largely
upon drivers ATF3, CYR61, EGR1, FN1 and PLAU and to some
extent MUC1. Clustering the three groups distinguishes the most
positive cluster (LPA-positive, N=33), a negative cluster (LPA-
negative, N=33) and a smaller cluster with differentially expressed
genes (Other, N=13) that has a distinct pattern from the other
groups. The Other cluster falls between the LPA-positive and -
negative clusters and could represent either a transitional state of
development between the two or a distinct set of ovarian tumors
driven LPA in the context of other factors.
The LPA-signature-positive cluster comprises significantly
shorter median values for both disease-specific (29 months,
*P=0.017) (Figure 2E) and progression-free (15 months,
*P=0.025) survival (Figure 2F) compared to the LPA-negative
cluster, which had median values of 58 and 25 months,
respectively. Statistical analysis of our findings indicated that this
classification had high sensitivity (0.88 and 0.94 for LDA and
KNN, respectively) for predicting relapse and high specificity (0.84
and 0.91 for LDA and KNN, respectively) for predicting short
relapse. Taken together, our analysis of the 39-gene signature in
prognosis of ovarian cancer suggests the signature represents
markedly reduced progression-free and disease-specific survival
and overall a worsened prognosis.
Claudin-1 is a biomarker for serous ovarian cancer and
transcriptionally regulated by LPA to facilitate ovarian
cancer cell adhesion
As therapeutics against LPA begin to enter clinical trials [36], a
biomarker capable of distinguishing among subtypes of EOC
could provide an extremely valuable classifier to select those
ovarian cancer patients who are most likely to benefit from LPA-
targeted drugs. Within the 39-gene LPA signature, we sought to
determine whether such a biomarker existed. Among hierarchical
Figure 1. 39-gene transcriptional signature clusters serous EOC samples from patient-derived gene expression data. Datasets were
downloaded from the NCBI Entrez GEO DataSets website and analyzed for gene expression changes among all included transcripts in the 39-gene
signature. Median values of transcripts contained in the LPA gene signature were clustered and average linkages were calculated using the Cluster
software. Results were visualized using the TreeView program (see methods). GSE6008, N=103. The strongly-positive LPA cluster, N=19, (mostly red)
is seen in the bracket on the far right corresponding to serous tumors. Statistical analysis compared normal control samples with ovarian tumor
samples of the types indicated and used ANOVA and Tukey’s Multiple comparison post test; **P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0005583.g001
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PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5583clustering analyses, particular gene expression transcripts repeat-
edly drive clustering and patient categorization. More specifically,
a combination of ATF3, CLDN1, CXCL1, CYR61, EGR1, FN1, IL-
8, MUC1, PLAU, THBS1 and TNC determine the LPA-positive
clusters (Figure 1, Figure S2, Figure 2A and 2D, and data not
shown) when these genes are included on the microarray chip.
Among these drivers, we sought to determine whether a singular
transcript is responsible for LPA-positive signature characteriza-
tion.
Using the most complete dataset we acquired, (GSE6008;
N=103) [24], we analyzed the drivers and determined whether
classification of LPA-positive serous tumors could be achieved
using only CLDN1, CYR61, FN1, IL-8, MUC1, THBS1 and TNC
(Figure S3A). The comprehensiveness of the dataset we selected
was based on the large number of samples, numbers of gene
transcripts on the microarray and diversity of tissue samples. Using
the available cell adhesion proteins, we revisited the data on
specimens acquired from patients at the Norwegian Radium
Hospital and found that hierarchical clustering of these genes was
able to recapitulate the prognosis trends we previously observed
for disease-specific and progression-free patient survival (Figure
S3B and S3C). Out of the seven drivers in this dataset, claudin-1
(CLDN1) was sufficient to differentiate serous from other EOC
types (Figure S3D). In comparison, serous carcinoma samples
expressed high levels of CLDN1 whereas mucinous and normal
were low and clear cell levels were the lowest. The endometrioid
samples included a few patients with high claudin-1 expression
(N=4, 11%) but the majority of samples were at the median level
or below (N=32, 89%). Further analyses showing individual
normalized comparison of gene expression levels (Figure 3)
demonstrates that CLDN1 distinguishes serous from normal, clear
cell, endometrioid and mucinous and is expressed at elevated
levels in serous (P,0.001) (Figure 3H).
Thus, we next sought to determine the association between LPA
and claudin-1 in ovarian cancer cells. Gene expression profiling of
CLDN1 in OVCAR-3 cells after 24 h of stimulation with LPA
(20 mM), EGF (20 mM) or TGFb (2 mM) demonstrated LPA
selectively increased CLDN1 expression (Figure 4A). To confirm
these results, we measured mRNA changes using quantitative,
real-time PCR and noted that LPA (10 mM) significantly increased
CLDN1 (P,0.01) compared to EGF (10 mM) after 24 h of agonist
treatment (Figure 4B). The LPA-mediated increase in CLDN1 is
maximal between 4 to 8 h after LPA (10 mM) treatment, when the
relative ratio is approximately 20 times above normalized control
(Figure 4C) CLND1 levels remain elevated at 24 h at approxi-
mately 1.5 to 3 times control levels (Figure 4C).
We next stimulated OVCAR-3 and HT-29 colon cancer cells
with 10 mM LPA for various times and examined effects on
claudin-1 localization. HT-29 cells were used as a model for
comparison to OVCAR-3 because claudin-1 is a regulator of
metastasis in colon cancer [37] and not all cell types express
claudin-1. Within 30 min after LPA stimulation, claudin-1
redistributed from the nuclear region to cell junctions in HT-29
cells. In contrast at 30 min of incubation with OVCAR-3 cells,
most of the claudin-1 staining was nuclear and only some occurred
on the plasma membrane and cell junctions (Figure 4D). Similar
claudin-1 staining was seen in OVCAR-3 at 240 min post LPA
stimulation (data not shown). However, intense cell junction
staining occurred at 1440 min after LPA addition (Figure 4D,
bottom right). Taken together, the data suggests that LPA induces
increase in mRNA levels for CLDN1, which is not replicated by
EGF, and LPA localizes claudin-1 to cell junctions in OVCAR-3
and HT-29 cells.
The previous results lead us to question whether the increase
and relocalization of claudin-1 altered cell adhesion in OVCAR-3
cells. We thus analyzed cell adhesion in the presence of LPA after
manipulating claudin-1 expression. Indeed, 10 mM LPA signifi-
cantly enhances OVCAR-3 cell adhesion under all transfection
conditions (Mock, RISC-free and siCldn1) when compared to
transfected cells without LPA present (Figure 4E, white vs. black
bars). A reduction in claudin-1 expression significantly reduced the
ability of LPA to enhance adhesion (Figure 4E). Taken together,
the data suggests that LPA enhances the adhesion of OVCAR-3
cells in part through increased expression and membrane
localization of claudin-1.
Claudin-1 localizes to tight junctions and plays a role in cell
adhesion. However a major reported role of LPA in ovarian
cancer cell signaling is induction of motility. To evaluate the role
of claudin-1 in ovarian cancer cell migration, we performed a
series of functional migration assays after manipulating claudin-1
expression in SKOV-3 cells using siRNA. Claudin-1 levels were
decreased approximately 60% (Figure 5A). SKOV-3 cells were
selected instead of OVCAR-3 cells because OVCAR-3 cells are
not motile and SKOV-3 cells are highly motile and responsive to
LPA [38]. SKOV-3 cells are a relevant model system since they
also show a similar LPA-mediated increase in CLDN1 to OVCAR-
3 cells at 24 hours (Figure 5B) and they independently verified the
39-gene signature (Table 1 and Figure S1).
Wounding confluent monolayers of SKOV-3 cells stimulated
with LPA (10 mM) and transfected with Mock-, RISC-free- or
claudin-1 siRNA showed an similar effects on healing in response
to LPA after 24 h (data not shown). Similar results were achieved
with proliferation assays (data not shown) where no significant
changes were measured comparing SKOV-3 cells with reduced
claudin-1 to controls. SKOV-3 cells with reduced claudin-1 were
also examined without exogenous LPA to determine their ability
to heal a wounded cell monolayer. We detected an inability to seal
wounded monolayers within 24 h, a process requiring LPA. We
also detected an abundance of detached cells floating throughout
the medium in wells with reduced claudin-1 expression (Figure 5C).
It is unclear what percentage of suspended cells observed in the
gap between monolayers were attached (reseeded cells) or not
Figure 2. The LPA signature corresponds to worsened outcome in ovarian cancer patients. (A) The patient dataset, GSE12418, N=54, was
downloaded from the NCBI Entrez GEO DataSets website and analyzed for gene expression changes among all included transcripts in the 39-gene
signature. Hierarchical clustering using the available genes divided patient samples into two groups, LPA-positive (N=24) and dissimilar (N=30)
clusters, based largely upon the drivers THBS1, EGR1, EPAS1, CYR61, FN1 and PLAU. (B) Separating the clusters based on stage IIIab or IIIc
demonstrated a greater portion of samples from stage IIIc patients (N=20, 83%, P=0.01) among the LPA-positive cluster whereas the dissimilar
cluster is evenly split between stage IIIab and IIIc. (C) Patient samples in the LPA-positive cluster also contained a greater percentage of deceased
patients (N=18; 67%) than the dissimilar cluster (N=16, 53%). Results from C were not statistically significant. (D) Specimens (N=79) isolated from
patients treated at the Norwegian Radium Hospital (see METHODS) were analyzed by gene expression profiling. Hierarchical clustering of available
genes included in the 39-gene signature separated the patients into three groups (LPA-positive, N=33; LPA-negative, N=32; Other, N=13) based
largely upon drivers ATF3, CYR61, EGR1, FN1 and PLAU. Kaplan-Meier analysis of the different clusters indicates that the LPA-signature positive cluster
has shorter median values for both disease-specific (29 months, P=0.017) (E) and progression-free (15 months, P=0.025) survival (F) compared to the
LPA-negative cluster (median values of 58 and 25 months, respectively).
doi:10.1371/journal.pone.0005583.g002
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5583Figure 3. CLDN1 is a biomarker for serous epithelial ovarian carcinoma specimens. Box-plot analyses of data from GSE6008, N=103 show
the drivers THBS1 (A, B), TNC (C), IL-8 (D), MUC1 (E, F), CYR61 (G), CLDN1 (H), KRT23 (I) and FN1 (J, K, L) normalized comparison of gene expression levels.
Among all previously-identified drivers in hierarchical clustering, the data demonstrates that CLDN1 is the only one which distinguishes serous when
compared with normal, clear cell, endometrioid and mucinous (***P,0.001). The box represents the range of values and the center vertical line inside
the box represent the median with whiskers representing the extended range. Results were analyzed by ANOVA and Tukey’s Multiple comparison
post test; **P,0.05, **P,0.01 and ***P,0.001 of ovarian tumor type vs. normal samples.
doi:10.1371/journal.pone.0005583.g003
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5583Figure 4. LPA mediates cell adhesion through claudin-1 in OVCAR-3 cells. (A) OVCAR-3 cells were stimulated with either LPA (20 mM), EGF
(20 mM) or TGFb (2 mM) for 24 h before processing for Affymetrix gene expression microarray. CLDN1 expression was normalized to untreated
controls and compared to agonist-stimulated conditions. Results are the average of triplicate samples. Results were analyzed by ANOVA and
Bonferroni’s post test; *p,0.05, LPA vs. Control. (B) OVCAR-3 cells were stimulated with either LPA (10 mM) or EGF (10 mM) for 24 h and processed for
quantitative RT-PCR (see methods) to measure transcriptional activity comparing selected transcripts from the 39-gene signature, claudin-1 (Cldn1),
SKI-like oncogene (Skil) and low density lipoprotein receptor (LDLR). Results were normalized to b2-microglobulin and reflect the average of triplicate
samples repeated in four independent assays. Results were analyzed by ANOVA and Bonferroni’s post test; **p,0.01, LPA vs. EGF. (C) A timecourse of
LPA (10 mM) stimulated OVCAR-3 cells was performed for the times indicated using quantitative RT-PCR. Results show a representative experiment
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PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5583(floating cells unable to reattach through loss of claudin-1), but
most cells were rounded and did not exhibit flattened morphology
associated with attachment. Reducing claudin-1 expression
resulted in a 9-fold and 10-fold increase in the number of
suspended cells detected in the space between monolayers
compared to Mock and RISC-free siRNA control conditions,
respectively (Figure 5D). These responses to claudin-1 siRNA
could not be attributed to variation of viability alone (Figure 5E)
and suggests that reducing claudin-1 allows SKOV-3 cells to
detach from confluent layers and float in suspension.
We compared the migratory capabilities of SKOV-3 cells with
Mock, RISC-free and claudin-1 siRNA-transfection. In response
to LPA (20 mM) stimulation in a Boyden chamber, an inhibition in
LPA-stimulated migration was observed in cells with reduced
claudin-1 compared to both Mock and RISC-free siRNA control
transfected cells (Figure 5F and G). The data suggests claudin-1
enhances LPA-mediated Boyden chamber migration in SKOV-3
cells and may reflect an inability of cells to attach to the
substratum required for Boyden chamber migration through
pores. This is a significant effect because motility is a major effect
of LPA on SKOV-3 cells.
Discussion
Herein we present several important findings: first, a 39-gene,
LPA-mediated signature identifies serous EOC as being different
from with other types of EOC; second, the 39-gene signature
correlates with worsened prognosis; third, a group of 7 genes is
sufficient to categorize the LPA signature; fourth, a single
biomarker, claudin-1, is increased in serous EOC and claudin-1
mRNA levels are increased by LPA; fifth, LPA induced claudin-1
localization to the plasma membrane; sixth, claudin-1 is involved in
LPA-mediated adhesion and migration. The 39-gene expression
signature was defined using OVCAR-3, an ascites-derived serous
EOC cell line. Given that elevated levels of LPA are present in the
vast majority of ascites fluids, OVCAR-3 is likely to have been
exposed to LPA in the tumor microenvironment, making it an ideal
model. It is intriguing that LPA stimulation was necessary in order
to define a gene expression profile reflective of serous ovarian
cancers suggesting that in vivo serous ovarian cancers are exposed
and responding to LPA. A number of components in the 39-gene
signature have been identified in previous ovarian candidate gene
studies [39–41] and other genes have known associations with LPA
[30–35]. However, the signature contains transcripts previously
unassociated with LPA, such as CLDN1, and additional experiments
are underway to elucidate these connections.
Using gene expression analysis and mining through ovarian
cancer patient datasets, we demonstrate that the 39-gene signature
characterizes serous EOC and a worsened prognosis. Comparing
disease specific survival and progression free survival of LPA-
signature-positive versus dissimilar groups, the LPA-positive
patients exhibit a significantly reduced time of survival. This is
remarkable considering that the preeminent biomarker among the
39-gene signature, claudin-1, was unfortunately absent from this
ovarian dataset.
Additionally, the worsened prognosis classified by the 39-gene
signature is observed when the comparison is made between
serous samples in different disease stages. Among serous
specimens, the LPA-positive group had a greater percentage of
stage IIIc serous carcinoma than stage IIIa and IIIb. This
observation is indicative of prognosis because the 5-year survival
for stage IIIa and IIIc carcinomas is 41.4% and 23.4%,
respectively.
The fact that claudin-1 was not included in every prognosis
dataset we analyzed indicates that the prognostic ability of the 39-
gene signature is not reliant upon on any singular gene expression
change, but rather likely represents the conglomerate result of
systematic changes resulting from LPA-induced changes in RNA
levels. We did, however, observe an ability to recapitulate the
serous EOC clustering using an abbreviated 7-gene signature that
included CLDN1, CYR61, FN1, IL-8, MUC1, TNC and THBS1.
Using these seven drivers, similar (and even enhanced) results were
achieved compared to using all 39-genes. It is possible that these
seven along with a few others (i.e. ATF3, EGR1, CXCL1, etc.)
represent the majority of the effects mediated by LPA in the tumor
microenvironment and that the others represent non-specific,
growth-factor induced transcriptional activity that could be related
to homeostatic regulation. Among signature drivers and the seven
drivers changes, many have known associations with LPA,
including CXCL1 [30], CYR61 [31], EGR1 [32], IL-8 [33], FN1
[34] and PLAU [35].
In this study CLDN1 is elevated in serous EOC and sufficient to
cluster ovarian tumor types, which suggests it, by itself, is an
ovarian cancer-type biomarker but not a prognostic biomarker.
This is in agreement with a previous study that distinguished
between endometrioid and serous carcinoma using immunohisto-
chemistry and claudin 1–7 expression [42]. Another independent
study found claudin-1, claudin-3 and claudin-7 up-regulation
together in ovarian cancer effusions predicts poor progression-free
and overall survival [43]. Unlike the aforementioned studies, ours
deviates because we use gene expression profiling, claudin-1, but
not claudin-3, -4 or -7 and we also include normal, mucinous and
clear cell tumors to further suggest that claudin-1 could distinguish
serous from the other histologic types. We were unable to assess a
prognostic ability of claudin-1 alone, in part because claudin-1 was
not available on the earlier microarray profiling used to collect
some of the patient data for analyses.
This study reports the novel observations that LPA markedly
increases claudin-1 transcription and enhances its localization to the
plasma membrane, likely into tight junctions. Cells lose adhesion
with the loss of tight junctional proteins, like claudins, thus allowing
the acquisition of migratory capabilities [44]. With reduced claudin-
1 expression, the data shows a decrease in OVCAR-3 adhesion, an
increase in the potential of SKOV-3 cells to detach and float in
medium and a decrease in LPA-mediated migration of SKOV-3
through a Boyden chamber. The latter is likely the result in an
inability of siClaudin-1 cells to adhere to the Boyden chamber
substratum required to migrate through the pores.
If we rationalize the data acquired in this study, what broader
influence does the LPA-mediated increase in claudin-1 have
during the progression of ovarian cancer? The answer may arise
out of the kind of disease spread that occurs—ovarian cancer
spreads intraperitoneally. Many cancers that progress to metastatic
tumors must acquire the ability to degrade the extracellular
that was repeated in OVCAR-3 and SKOV-3 cells. ***P,0.001 for 1,4,8 and 24 h time points compared with normalized control. (D) Quiescent HT-29
and OVCAR-3 cells were stimulated with LPA (10 mM) for the times indicated and visualized using anti-claudin1 primary antibody followed by Alexa
goat anti-mouse fluorescent secondary. (E) OVCAR-3 cells were transfected with siRNA targeting claudin-1 for 48 h. Cells were then trypsinized and
replated for 2 h in the presence or absence of LPA (10 mM) and analyzed for adhesion. Results were analyzed by ANOVA and Bonferroni’s post test;
*p,0.05 (RISC with LPA vs. siCldn1 with LPA) and **p,0.01 (Mock with LPA vs. siCldn1 with LPA).
doi:10.1371/journal.pone.0005583.g004
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turbulent anoikis conditions in the circulation and complete
extravasion to invade new tissues. The ovaries are located in the
peritoneal cavity, creating a uniquely passive, and comparatively
uncomplicated, metastasis scenario. Malignant ovarian tumor cells
floating in ascites fluid or peritoneal washings are detected in stage
Ic ovarian cancer and above [45], making cells shed from the
primary ovarian tumor commonly observed in this disease. These
shed cells are then passively transported by peritoneal fluid and
can seed on surrounding tissues if they acquire the ability to
implant on peritoneal surfaces [15,45]. What molecular proteins
would be necessary to assist implantation of free-floating cells onto
peritoneal surfaces? Cell adhesion molecules. Corroborating
observations include the fact that normal ovarian surface
epithelium rarely expresses E-cadherin [19] but ovarian carcino-
mas express high levels of E-cadherin and other cell adhesion
molecules [46]. Further, the 39-gene signature that is rich with key
cell adhesion transcripts such as: CLDN1, FN1, MUC1, THBS1 and
TNC, along with cytokines that promote or regulate adhesion,
CYR61 and IL-8.
In summary, we have identified an LPA-driven, 39-gene
signature that is sufficient on unsupervised clustering to predict
worsened outcome in ovarian cancer. While some of the effect on
outcome could be related to the signature enriched in serous
epithelial tumors that are associated with a worsened outcome, this
appears insufficient to explain the overall effect on tumor
behavior. Thus, an LPA signature likely reflective of LPA function
in ovarian cancer patients is highly enriched in a population of
ovarian cancers. This could prove to be important in determining
prognosis, in response to current therapy or in selecting patients
for therapy targeting LPA. Claudin-1 is a leading candidate
biomarker for such selection as LPA-targeted therapies move
forward to clinical trials. This is particularly important as a series
of inhibitors targeting LPA signaling, LPA production and LPA
receptors are indeed in preclinical development [36]. In addition,
the demonstration herein that LPA signaling alters outcome in
ovarian cancer increases the impetus for clinical trials of drugs
targeting this pathway.
Supporting Information
Figure S1 Comparison and validation of the LPA-induced gene
expression transcriptional profile in OVCAR-3 cells. Pairwise
scatter plots demonstrate the microarray gene expression values of
the triplicate samples under one experimental condition of either
(A) control or (B) LPA-stimulated (18:1, 20 mM for 24 h) or (C)
EGF-stimulated (20 mM for 24 h). In the first row of three plots
the line represents sample 1 with itself (hyb.1), sample 1 with
sample 2 (hyb.2) and sample 1 with sample 3 (hyb.3). The
comparisons continue with the other rows so that the three plots
on the upper right half are mirrors of the three in the lower half.
Because the corresponding dots fall close within a 45u reference
line, the replicated microarray chips are highly correlated,
suggesting the reproducibility of each condition is high. (D)
Quantitative RT-PCR of OVCAR-3 cells stimulated without or
with LPA (20 mM) for the times indicated. The mRNA was
extracted from OVCAR-3 cells and processed to corroborate
transcript changes seen on the microarray. The data shown is the
average of results from transcription factors and a co-repressor in
OVCAR-3 and SKOV-3 cells relative to Beta-2 microglobulin.
The Expression Analysis Systematic Explorer (EASE) software
program was used to categorize microarray results into (E) cellular
localization or (F) molecular function. The majority of genes are
localized to regions affecting extracellular signaling including the
plasma membrane (30%), extracellular matrix (12%) or secretion
into the extracellular space (20%). A variety of molecular functions
are represented in the signature with cell-cell communication
(21%) and signal transduction (14%) the most prominent
categories.
Found at: doi:10.1371/journal.pone.0005583.s001 (1.60 MB TIF)
Figure S2 Various ovarian cancer datasets demonstrate that the
39-gene signature characterizes serous EOC. (A) The patient
dataset GSE6822 (N=74) [25] was examined with the genes
available contained in the 39-gene signature and hierarchical
clustering separated a group (N=19) that was strongly positive for
the LPA-signature (far right cluster) and corresponded most closely
with invasive serous EOC. (B) The patient dataset GSE10971
(N=37) was divided into two groups based upon similarity to the
LPA signature as determined by increased expression and
hierarchical clustering (data not shown). All patients in the LPA-
positive cluster (100%) had high-grade serous carcinoma while the
majority of patients in the dissimilar cluster (N=24 out of 25) had
non-malignant fallopian tube epithelium carcinoma.
Found at: doi:10.1371/journal.pone.0005583.s002 (1.79 MB TIF)
Figure S3 CLDN-1 and cell adhesion-related proteins drive the
clustering of the LPA transcriptomic signature. (A) The patient
dataset, GSE6008, N=103, was downloaded from the NCBI
Entrez GEO DataSets website and analyzed using a previously-
identified set of drivers, CLDN1, CYR61, FN1, IL-8, MUC1,
THBS1, and TNC. These genes were capable of classifying the
LPA-positive serous cluster of patient samples without the other
genes comprising the 39-gene signature. Specimens (N=79)
isolated from patients treated at the Norwegian Radium Hospital
Figure 5. Reduced claudin-1 expression enhances suspended cells and impairs LPA-mediated Boyden chamber migration using
SKOV-3 ovarian cancer cells. (A) Protein from SKOV-3 cells transfected with siRNA was harvested and processed for Western blotting.
Immunoblots were probed with claudin-1 and GAPDH antibodies and visualized with chemiluminescence. The bands were quantified using ImageJ
and normalized to Mock control. Claudin-1 expression was consistently decreased .50%. (B) Quantitative RT-PCR showing modulation of claudin-1
mRNA transcript in SKOV-3 cells in response to LPA treatment for the times indicated. Quantification is normalized to b2-microglobulin, **P,0.01 for
4 h and ***P,0.001 for 1, 2, 8 and 24 h time points compared with normalized control. (C) siRNA transfected SKOV-3 cells were plated in triplicate 12-
wells and grown to confluence. Confluent monolayers were then scratched with a pipette tip, rinsed five times in serum-free media (SFM) to remove
floating cells, placed in SFM and incubated for 24 h. Microscopic images (46and 106) shown are representative (Mock and RISC-free control were
identical) of repeated results. Photomicrographs show few cells in the wound (Mock, 46) versus numerous cells in the wound (siCldn1, 46and 106)
between monolayers. (D) Quantification of cells in the wounded area from C. ***p,0.001 from ANOVA and Bonferroni’s test. (E) Cells from D were
examined for viability by detachment from 12-well dishes and plating 5–20610
4 in 96-well plates in quadruplicates. Cells were grown for 24 h in 1%
medium before adding CellTiter
TM Blue reagent to wells overnight to measure colorimetric change indicating cell viability. (F) Approximately 2610
5
SKOV-3 cells were plated in 6-well dishes overnight prior to transfection with reagent only and no siRNA (Mock), RISC-free control siRNA or claudin-1
siRNA. Forty-eight hours later, cells were then seeded in Boyden chambers and stimulated overnight with LPA (20 mM) or not (No LPA) to facilitate
directed migration through the chamber. (G) Transwells were stained with crystal violet and fields were examined to determine the number of cells
that migrated through the pores. Results represent the average of quadruplicate transwells, six fields measured in each transwell and repeated
experiments. **p,0.01; LPA-stimulated RISC-free control vs. LPA-stimulated siClaudin-1.
doi:10.1371/journal.pone.0005583.g005
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PLoS ONE | www.plosone.org 13 May 2009 | Volume 4 | Issue 5 | e5583re-examined by hierarchical clustering using only those available
genes with a role in cell adhesion. Kaplan-Meier analysis of the
different clusters indicates that the LPA-signature positive cluster
has shorter median values for both disease-specific (B) and
progression-free (C) survival compared to the LPA-negative
cluster. (D) Out of the seven drivers in A, claudin-1 (CLDN1)
was sufficient to differentiate serous from other EOC types. Serous
EOC highly expresses CLDN1 whereas mucinous tumors, clear
cell tumors and normal specimens were low and the majority of
endometrioid samples are at the median level or below (N=32,
89%).
Found at: doi:10.1371/journal.pone.0005583.s003 (2.23 MB TIF)
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